Dr Reddy’s Laboratories (RDY) has released an update.
Dr. Reddy’s Laboratories reported a robust second quarter for FY25, showcasing a 17% year-over-year revenue growth, achieving their highest ever quarterly sales and profit before tax. The company highlighted its strategic acquisition of the NRT portfolio and a successful stock split, boosting investor confidence. A collaborative effort with Nestlé India further strengthens its nutraceuticals business, positioning Dr. Reddy’s for continued growth.
For further insights into RDY stock, check out TipRanks’ Stock Analysis page.
